What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants?

Phase 4

Withdrawn

• Conditions: heart attack; myocardial infarction; 10064477; 10011082; 10014523

• Registration Number: NL-OMON49131
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 2500

Inclusion Criteria

Over 18 years of age
Acute coronary syndrome with elevated cardiac enzymes
Atrial fibrillation with long-term indication for oral anticoagulation

Exclusion Criteria

Severe bleeding in past 3 months
Known coagulopathy
Contra-indications for intended medication (NOAC, P2Y12-remmer, ASA)
eGFR < 15 min/kg/1.73m2

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary efficacy endpoint: composed endpoint of all-cause death, MI, stroke,<br /><br>systemic embolism, stent thrombosis.<br /><br>Primary safety endpoint: ISTH major + clinically relevant non-major bleeding.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints: separate components of primary endpoints, net clinical<br /><br>benefit, quality of life.</p><br>